The WHO CNS5 recognizes TP53 alterations as common in both primary and secondary glioblastoma, and TP53 mutation status may impact therapeutic decision making, for example, regarding temozolomide sensitivity and clinical trial eligibility [3]. The gene discussed is TP53; the disease is glioblastoma.